Roche Strengthens Immunology Pipeline with Promising Phase III Results Supporting Gazyva in Lupus Treatment

Roche Strengthens Immunology Pipeline with Promising Phase III Results Supporting Gazyva in Lupus Treatment

(IN BRIEF) Roche has reached a key regulatory milestone with the FDA’s acceptance of its application for Gazyva/Gazyvaro as a treatment for systemic lupus erythematosus. The submission is based on strong phase III trial data showing significant improvements in disease activity, remission rates, and flare reduction compared to standard therapy alone. If approved, the therapy would become the first anti-CD20 treatment specifically targeting B cells in SLE, potentially establishing a new standard of care. With millions of people affected worldwide and limited targeted treatment options available, the development represents an important step forward in managing this complex autoimmune disease. The therapy’s established safety profile and expanding clinical evidence across related conditions further support its potential role in immunology.

(PRESS RELEASE) BASEL, 21-Apr-2026 — /EuropaWire/ — Roche has announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Gazyva/Gazyvaro (obinutuzumab) as a potential treatment for systemic lupus erythematosus (SLE). The submission is supported by results from the phase III ALLEGORY trial, which demonstrated meaningful clinical improvements compared to placebo. A regulatory decision is expected by December 2026. The therapy is already approved in the U.S. and EU for adults with lupus nephritis.

If approved, Gazyva/Gazyvaro would represent the first anti-CD20 therapy specifically targeting B cells in SLE, offering a new approach to managing the disease. SLE is a chronic autoimmune condition affecting more than three million people globally, often leading to organ damage and significant quality-of-life challenges if not effectively controlled.

Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, highlighted the importance of this milestone, noting that the therapy has the potential to improve disease control, increase remission rates, and reduce dependence on long-term steroid treatments.

The ALLEGORY study showed that 76.7% of patients treated with Gazyva/Gazyvaro alongside standard therapy achieved a clinically meaningful improvement in disease activity, compared to 53.5% of those receiving placebo. The results demonstrated strong statistical significance and reflected improvements in symptoms, physical condition, and overall disease severity at 52 weeks.

Beyond the primary endpoint, the therapy showed consistent benefits across multiple secondary measures. Patients receiving the treatment experienced fewer disease flares, improved outcomes in composite lupus assessments, and a significant increase in remission rates. The likelihood of achieving remission more than doubled compared to placebo, while disease activity at low levels was also significantly improved. Importantly, the safety profile remained consistent with previous data, with no new safety concerns identified.

Albert T. Roy, President and CEO of the Lupus Research Alliance, emphasized the potential impact of a new treatment option for people living with SLE, highlighting the need for therapies that can better control symptoms and reduce the frequency of disease flares.

The data supporting the submission were presented at the European Lupus meeting SLEuro 2026 and published in the New England Journal of Medicine earlier this year. Roche has also submitted the same data package to the European Medicines Agency for review.

Gazyva/Gazyvaro is a humanised monoclonal antibody designed to target CD20 proteins on B cells, promoting their destruction and enhancing immune system responses through increased antibody-dependent cellular cytotoxicity. The therapy is already approved in over 100 countries for the treatment of various blood cancers.

The ALLEGORY trial is part of a broader clinical programme evaluating Gazyva/Gazyvaro across multiple immune-mediated conditions, including lupus nephritis, idiopathic nephrotic syndrome, and primary membranous nephropathy. These studies collectively support the therapy’s potential to address a wide range of autoimmune diseases.

Systemic lupus erythematosus remains a complex and often unpredictable condition, affecting multiple organ systems such as the skin, joints, and kidneys. Many patients experience delays in diagnosis and repeated disease flares, which can lead to long-term complications. Approximately half of individuals diagnosed with SLE develop lupus nephritis within five years, underscoring the need for effective, targeted treatments.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Yap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci. 2019 Dec 10;20(24):6231.
[2] Furie RA, et al. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. NEJM. [Internet; cited 2026 March 24]. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150.
[3] Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42.
[4] Tian J, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023 Mar;82(3):351-56.
[5] Rees F, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-61.
[6] John Hopkins Medicine. Types of Lupus. [Internet; cited 2026 March 24]. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/lupus/types-of-lupus
[7] Kandane-Rathnayake R, et al. Association of Lupus Low Disease Activity State And Remission With Reduced Organ Damage And Flare in Systemic lupus erythematosus Patients With High Disease Activity. Rheumatology (Oxford). 2025 May 1;64(5):2741-48.
[8] Nightingale AL, et al. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med. 2017 Feb 10;4(1):e000172.
[9] Murimi-Worstell IB, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020 May 21;10(5):e031850.
[10] Mahajan A, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020 Sep;29(9):1011-20.
[11] Bechler KK, et al. Predicting patients who are likely to develop Lupus Nephritis of those newly diagnosed with Systemic Lupus Erythematosus. AMIA Annu Symp Proc. 2023 Apr 29:2022:221-30.
[12] Hocaoglu M et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the Lupus Midwest Network. Arthritis & Rheumatol 2023 Apr;75(4):567-73.
[13] Mok C, et al. Treatment of lupus nephritis: consensus evidence and perspectives. Nat Rev Rheumatol. 2023 Apr;19(4):227-38.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

SOURCE: Roche